131 related articles for article (PubMed ID: 31350126)
1. Novel SAR for quinazoline inhibitors of EHMT1 and EHMT2.
Leenders R; Zijlmans R; van Bree B; van de Sande M; Trivarelli F; Damen E; Wegert A; Müller D; Ehlert JE; Feger D; Heidemann-Dinger C; Kubbutat M; Schächtele C; Lenstra DC; Mecinović J; Müller G
Bioorg Med Chem Lett; 2019 Sep; 29(17):2516-2524. PubMed ID: 31350126
[TBL] [Abstract][Full Text] [Related]
2. Cycloalkane analogues of sinefungin as EHMT1/2 inhibitors.
Liu Q; Cai X; Yang D; Chen Y; Wang Y; Shao L; Wang MW
Bioorg Med Chem; 2017 Sep; 25(17):4579-4594. PubMed ID: 28739157
[TBL] [Abstract][Full Text] [Related]
3. EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression.
Renneville A; Van Galen P; Canver MC; McConkey M; Krill-Burger JM; Dorfman DM; Holson EB; Bernstein BE; Orkin SH; Bauer DE; Ebert BL
Blood; 2015 Oct; 126(16):1930-9. PubMed ID: 26320100
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines.
Katayama K; Ishii K; Tsuda E; Yotsumoto K; Hiramoto K; Suzuki M; Yasumatsu I; Igarashi W; Torihata M; Ishiyama T; Katagiri T
Bioorg Med Chem Lett; 2020 Oct; 30(20):127475. PubMed ID: 32781218
[TBL] [Abstract][Full Text] [Related]
5. MDC1 methylation mediated by lysine methyltransferases EHMT1 and EHMT2 regulates active ATM accumulation flanking DNA damage sites.
Watanabe S; Iimori M; Chan DV; Hara E; Kitao H; Maehara Y
Sci Rep; 2018 Jul; 8(1):10888. PubMed ID: 30022091
[TBL] [Abstract][Full Text] [Related]
6. Towards the understanding of the activity of G9a inhibitors: an activity landscape and molecular modeling approach.
López-López E; Rabal O; Oyarzabal J; Medina-Franco JL
J Comput Aided Mol Des; 2020 Jun; 34(6):659-669. PubMed ID: 32060676
[TBL] [Abstract][Full Text] [Related]
7. Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.
Lu Z; Tian Y; Salwen HR; Chlenski A; Godley LA; Raj JU; Yang Q
Anticancer Drugs; 2013 Jun; 24(5):484-93. PubMed ID: 23466651
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel quinoline inhibitor for EHMT2/G9a through virtual screening.
Charles MRC; Mahesh A; Lin SY; Hsieh HP; Dhayalan A; Coumar MS
Biochimie; 2020 Jan; 168():220-230. PubMed ID: 31756401
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic priming by EHMT1/EHMT2 in acute lymphoblastic leukemia induces TP53 and TP73 overexpression and promotes cell death.
Silva-Carvalho AÉ; Alencar APD; Resende MR; da Costa DF; Nonino A; Neves FAR; Saldanha-Araujo F
Toxicol In Vitro; 2020 Dec; 69():104992. PubMed ID: 32889036
[TBL] [Abstract][Full Text] [Related]
10. Properly substituted analogues of BIX-01294 lose inhibition of G9a histone methyltransferase and gain selective anti-DNA methyltransferase 3A activity.
Rotili D; Tarantino D; Marrocco B; Gros C; Masson V; Poughon V; Ausseil F; Chang Y; Labella D; Cosconati S; Di Maro S; Novellino E; Schnekenburger M; Grandjenette C; Bouvy C; Diederich M; Cheng X; Arimondo PB; Mai A
PLoS One; 2014; 9(5):e96941. PubMed ID: 24810902
[TBL] [Abstract][Full Text] [Related]
11. In Silico Molecular Docking and Dynamics Simulation Analysis of Potential Histone Lysine Methyl Transferase Inhibitors for Managing β-Thalassemia.
Ravikumar Y; Koonyosying P; Srichairatanakool S; Ponpandian LN; Kumaravelu J; Srichairatanakool S
Molecules; 2023 Oct; 28(21):. PubMed ID: 37959685
[TBL] [Abstract][Full Text] [Related]
12. EHMT1/EHMT2 in EMT, cancer stemness and drug resistance: emerging evidence and mechanisms.
Nachiyappan A; Gupta N; Taneja R
FEBS J; 2022 Mar; 289(5):1329-1351. PubMed ID: 34954891
[TBL] [Abstract][Full Text] [Related]
13. Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1.
Cho HS; Kelly JD; Hayami S; Toyokawa G; Takawa M; Yoshimatsu M; Tsunoda T; Field HI; Neal DE; Ponder BA; Nakamura Y; Hamamoto R
Neoplasia; 2011 Aug; 13(8):676-84. PubMed ID: 21847359
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a.
Liu F; Chen X; Allali-Hassani A; Quinn AM; Wasney GA; Dong A; Barsyte D; Kozieradzki I; Senisterra G; Chau I; Siarheyeva A; Kireev DB; Jadhav A; Herold JM; Frye SV; Arrowsmith CH; Brown PJ; Simeonov A; Vedadi M; Jin J
J Med Chem; 2009 Dec; 52(24):7950-3. PubMed ID: 19891491
[TBL] [Abstract][Full Text] [Related]
15. Euchromatin histone methyltransferase II (EHMT2) regulates the expression of ras-related GTP binding C (RRAGC) protein.
Hwang S; Kim S; Kim K; Yeom J; Park S; Kim I
BMB Rep; 2020 Nov; 53(11):576-581. PubMed ID: 32684241
[TBL] [Abstract][Full Text] [Related]
16. IVMBIX-01294, an inhibitor of the histone methyltransferase EHMT2, disrupts histone H3 lysine 9 (H3K9) dimethylation in the cleavage-stage porcine embryo.
Park KE; Johnson CM; Cabot RA
Reprod Fertil Dev; 2012; 24(6):813-21. PubMed ID: 22781932
[TBL] [Abstract][Full Text] [Related]
17. A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma.
Yuan Y; Wang Q; Paulk J; Kubicek S; Kemp MM; Adams DJ; Shamji AF; Wagner BK; Schreiber SL
ACS Chem Biol; 2012 Jul; 7(7):1152-7. PubMed ID: 22536950
[TBL] [Abstract][Full Text] [Related]
18. Differential patterns of histone methylase EHMT2 and its catalyzed histone modifications H3K9me1 and H3K9me2 during maturation of central auditory system.
Ebbers L; Runge K; Nothwang HG
Cell Tissue Res; 2016 Aug; 365(2):247-64. PubMed ID: 27083448
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of histone methyltransferase EHMT2 in CD4
Colaço CS; de Matos AR; Estrêla MS; Rocha-Júnior MC; Otaguiri KK; Rodrigues ES; Takayanagui OM; Covas DT; Kashima S; Pittella Silva F; Haddad R
Arch Virol; 2017 Oct; 162(10):3131-3136. PubMed ID: 28608127
[TBL] [Abstract][Full Text] [Related]
20. The discovery of novel histone lysine methyltransferase G9a inhibitors (part 1): molecular design based on a series of substituted 2,4-diamino-7- aminoalkoxyquinazoline by molecular-docking-guided 3D quantitative structure-activity relationship studies.
Feng T; Wang H; Zhang X; Sun H; You Q
Med Chem; 2014 Jun; 10(4):426-40. PubMed ID: 24151879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
